PHASEBIO PHARMACEUTICALS INC (PHAS) Stock Overview
USA - NASDAQ:PHAS - US7172241090 - Common Stock
PHAS Key Statistics, Chart & Performance
The current stock price of PHAS is 0.0701 USD. In the past month the price decreased by -61.78%. In the past year, price decreased by -98.16%.
PHAS Latest News, Press Relases and Analysis
PHAS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About PHAS
Company Profile
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
Company Info
PHASEBIO PHARMACEUTICALS INC
1 Great Valley Pkwy Ste 30
Malvern PENNSYLVANIA 19355 US
CEO: Jonathan P. Mow
Employees: 60
Phone: 16109816500.0
PHASEBIO PHARMACEUTICALS INC / PHAS FAQ
What does PHAS do?
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
What is the current price of PHAS stock?
The current stock price of PHAS is 0.0701 USD. The price decreased by -26.21% in the last trading session.
Does PHAS stock pay dividends?
PHAS does not pay a dividend.
How is the ChartMill rating for PHASEBIO PHARMACEUTICALS INC?
PHAS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is PHAS stock listed?
PHAS stock is listed on the Nasdaq exchange.
What do analysts say about PHASEBIO PHARMACEUTICALS INC (PHAS) stock?
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
Can you provide the growth outlook for PHASEBIO PHARMACEUTICALS INC?
The Revenue of PHASEBIO PHARMACEUTICALS INC (PHAS) is expected to decline by -64.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
PHAS Technical Analysis
PHAS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAS. Both the profitability and financial health of PHAS have multiple concerns.
PHAS Financial Highlights
Over the last trailing twelve months PHAS reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 36.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -12572.13% | ||
| ROA | -463.95% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PHAS Forecast & Estimates
7 analysts have analysed PHAS and the average price target is 1.02 USD. This implies a price increase of 1355.06% is expected in the next year compared to the current price of 0.0701.
For the next year, analysts expect an EPS growth of 59.21% and a revenue growth -64.49% for PHAS